Literature DB >> 9058721

HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes.

J P Truman1, C Choqueux, J Tschopp, J Vedrenne, F Le Deist, D Charron, N Mooney.   

Abstract

HLA class II molecules, expressed on the surface of antigen-presenting cells, are responsible for the presentation of antigen-derived peptides to CD4+ helper T lymphocytes. Signaling via these molecules initiates the generation of second messengers leading to programed cell death (PCD) of activated B lymphocytes. The present study examined the mechanism of HLA class II-mediated apoptosis and describes the essential role of the molecule Fas and its ligand (FasL). FasL was expressed in B lymphocytes after stimulation via HLA class II or with phorbol esters. Expression of FasL protein was significantly increased in 50% of B lymphocytes after stimulation via HLA class II, and the level of FasL mRNA was also increased either by activation with phorbol esters and ionomycin or by signaling via HLA class II. Although HLA class II signaling did not change the expression of the Fas molecule, it did lead to increased sensitivity to Fas-mediated apoptosis. The crucial role of Fas/FasL interactions was confirmed by the absence of cell death via HLA class II in B cells lacking Fas expression, and by the significant inhibition of HLA class II-mediated apoptosis in the presence of either an antagonistic anti-Fas or anti-FasL antibody. These data demonstrate FasL expression on activated human B lymphocytes and support the idea that antigen presentation could contribute to the regulation of lymphocyte populations via Fas and FasL interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058721

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

2.  MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.

Authors:  Lei Jin; John C Stolpa; Ryan M Young; Aimee E Pugh-Bernard; Yosef Refaeli; John C Cambier
Journal:  Immunol Lett       Date:  2007-12-26       Impact factor: 3.685

Review 3.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

4.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

5.  High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

Authors:  Christina Hausl; Rafi U Ahmad; Maria Sasgary; Christopher B Doering; Pete Lollar; Günter Richter; Hans Peter Schwarz; Peter L Turecek; Birgit M Reipert
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

6.  Major histocompatibility complex class II inhibits fas antigen-mediated gastric mucosal cell apoptosis through actin-dependent inhibition of receptor aggregation.

Authors:  Calin Stoicov; Xun Cai; Hanchen Li; Kristine Klucevsek; Jane Carlson; Reza Saffari; Jeanmarie Houghton
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Activation-induced T cell death, and aberrant T cell activation via TNFR1 and CD95-CD95 ligand pathway in stable cardiac transplant recipients.

Authors:  H J Ankersmit; B Moser; A Zuckermann; G Roth; S Taghavi; M Brunner; E Wolner; G Boltz-Nitulescu
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

8.  Caspase activity is required for commitment to Fas-mediated apoptosis.

Authors:  V L Longthorne; G T Williams
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

9.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12

Review 10.  B cell MHC class II signaling: A story of life and death.

Authors:  Divya Sai Katikaneni; Lei Jin
Journal:  Hum Immunol       Date:  2018-04-30       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.